Stockscreener 앱 받기
7.29
1.88%
-0.14
시간 외 거래:
7.58
0.29
+3.98%
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline - Investing.com
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight - GlobeNewswire Inc.
Microtomes Market Projected To Witness Substantial Growth, - openPR.com
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? - TradingView
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus
Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire
New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga
Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com
Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance
Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus
8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Genetic Screening Testing for Preventive Health Market Top - openPR.com
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com
Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus
Myriad Genetics Announces Inducement Awards - GlobeNewswire
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Myriad Genetics appoints new CCO to drive growth By Investing.com - Investing.com South Africa
Myriad Genetics appoints new CCO to drive growth - Investing.com Australia
Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer - MarketScreener
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - GlobeNewswire
Healthcare Tech Leader From Amazon and Illumina Takes Commercial Helm at Myriad Genetics - Stock Titan
Myriad Genetics stock hits 52-week low at $8.44 amid market challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $8.44 amid market challenges - Investing.com
Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsMYGN - ACCESS Newswire
10 Analysts Assess Myriad Genetics: What You Need To Know - Benzinga
(MYGN) Technical Data - news.stocktradersdaily.com
Scotiabank cuts Myriad Genetics target to $20, keeps outperform rating By Investing.com - Investing.com Canada
Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN
Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Trend Tracker for (MYGN) - Stock Traders Daily
Global Preventive Healthcare Technologies And Services Market - openPR
The Future of Genetic Testing: Industry Growth, Trends & Key - openPR
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga
Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com
Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com
Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
0.42%
자본화:
|
볼륨(24시간):